Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Open accessThe DOI matches its Crossref record; 223 of the 223 references it cites were found in a registry or an index.
Abstract
The "Amyloid Cascade Hypothesis" has dominated the Alzheimer's disease (AD) field in the last 25 years. It posits that the increase of amyloid-β (Aβ) is the key event in AD that triggers tau pathology followed by neuronal death and eventually, the disease. However, therapeutic approaches aimed at decreasing Aβ levels have so far failed, and tau-based clinical trials have not yet produced positive findings. This begs the question of whether the hypothesis is correct. Here we have examined literature on the role of Aβ and tau in synaptic dysfunction, memory loss, and seeding and spreading of AD, highlighting important parallelisms between the two proteins in all of these phenomena. We discuss novel findings showing binding of both Aβ and tau oligomers to amyloid-β protein precursor (AβPP), and the requirement for the presence of this protein for both Aβ and tau to enter neurons and induce abnormal synaptic function and memory. Most importantly, we propose a novel view of AD pathogenesis in which extracellular oligomers of Aβ and tau act in parallel and upstream of AβPP. Such a view will call for a reconsideration of therapeutic approaches directed against Aβ and tau, paving the way to an increased interest toward AβPP, both for understanding the pathogenesis of the disease and elaborating new therapeutic strategies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRx0237 (21, LMTX) is a tau aggregation inhibitor.465”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [465]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Also, tau pathology is likely to begin in EC then move to the hippocampus, and ultimately invading the cortex, following an overlapping path existing among functionally connected areas [55, 157, 158, 177].”
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · cited 3×
“Unfortunately, while the “Oligomer Hypothesis” is still a matter of investigation, and data are being gathered to test the grounds of its premises, the clinical failure of most of the anti-A (cid:2) drugs has strongly destabilized this concept.”
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“Second, we know since the 1990 s that there is no correlation between A (cid:2) deposition and clinical degree of dementia among affected individuals [25–28], and plaques might occur in the brains of individuals with no sign of dementia [27, 29, 30].”
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“This was predicted by a study showing that all of the soluble oligomers tested including β-synuclein, islet amyloid polypeptide, polyglutamine, lysozyme, human insulin, and prion peptide 106–126, display a common conformation-dependent structure that is unique to soluble oligomers [193], By now, a variety of studies h…”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“This temporal sequence derives from studies in patients with FAD, where the genetic-driven increase of Aβ is followed by NFT accumulation [194], whereas the increase of tau, as in tauopathies, is not associated with Aβ deposition.”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Cited by
Items 101–200 of 314
Reich, N., Allsop, D., Parkin, E. T., & Dawson, N. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18477 · Cited by 15
“Interestingly, the spread of Tau, as assessed by Braak staging in AD, 11 is more strongly correlated with cognitive decline and the appearance of clinical symptoms than A β pathology, 6,7,12 suggesting that the propagation of Tau is a primary driver of the disease.”
BackgroundContemporary trends in targeted protein degradation for neurodegenerative diseases
Kumar, G., Thakur, V., Sardana, S., Tiwari, V. K., Sharma, D., & Kumar, A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118110 · Cited by 15
Chen, L., Liu, Y., Jia, P., Zhang, H., Yin, Z., Hu, D., Ning, H., & Ge, Y. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-20051-1 · Cited by 17
“The abnormal expression of Tau leads to the dysfunction of nerve cell, resulting in neurological diseases by reducing microtubule assembly and increasing microtubule instability (Gulisano et al. 2018).”
BackgroundWhiteaker, P., & George, A. A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106743 · Cited by 15
Vascular Function and Ion Channels in Alzheimer's Disease
Taylor, J. L., Baudel, M. A. S. M., Nieves‐Cintrón, M., & Navedo, M. F. (2024) · Microcirculation · doi:10.1111/micc.12881 · Cited by 15
“Alzheimer's disease manifests as cognitive decline, loss of motor function, and behavioral changes that are traditionally attributed to the pathological accumulation of amyloid beta (Aβ) and tau protein within the brain, resulting in neurode-generation [6].”
Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer’s Disease
Abdelhamid, M., Counts, S., Zhou, C., Hida, H., Kim, J., Michikawa, M., & Jung, C. (2025) · Nutrients · doi:10.3390/nu17030558 · Cited by 18
“However, some researchers argue that A β may be a consequence of the disease rather than its cause [76,105–108].”
Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates
Hovakimyan, A., Zagorski, K., Chailyan, G., Antonyan, T., Melikyan, L., Petrushina, I., Batt, D. G., King, O., Ghazaryan, M., Donthi, A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00544-3 · Cited by 16
Hossen, F., Geng, X. H., Sun, G. Y., Yao, X., & Lee, J. C. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04138-z · Cited by 13
“In fact, the oligomeric forms of Aβ and Tau have been implicated in the activation of the cerebral vascular endothelium, leading to neuroinflammation [69–75].”
Komal, K., Ghosh, R., Sil, D., Sharma, R., Kumar, S., Pandey, P., & Kumar, M. (2025) · Inflammopharmacology · doi:10.1007/s10787-024-01636-3 · Cited by 16
“Abnormal tau phosphorylation has been correlated to misfolding and protein deposition in brain (AD) (Gulisano et al. 2018).”
Proteomic Insight Into Alzheimer's Disease Pathogenesis Pathways
Ryu, T., Kim, K., Asiimwe, N., & Na, C. H. (2025) · PROTEOMICS · doi:10.1002/pmic.202400298 · Cited by 14
“The pathogenesis mechanisms of AD are still elusive, with hallmark features such as the extracellular accumulation of amyloid-beta (A β ) plaques [3] and intracellular neurofibrillary tangles (NFT) primarily composed of hyperphosphorylated tau protein [4].”
Moallemian, S., Salmon, É., Bahri, M. A., Beliy, N., Delhaye, E., Balteau, E., Degueldre, C., Phillips, C. L. M., & Bastin, C. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.08.001 · Cited by 16
Zamanian, M. Y., Khachatryan, L., Heidari, M., Darabi, R., Golmohammadi, M., Al-Aouadi, R. F. A., & Akkol, E. K. (2025) · BioFactors · doi:10.1002/biof.70047 · Cited by 15
Krishna-K, K., Behnisch, T., & Sajikumar, S. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215718 · Cited by 12
Understanding Alzheimer’s Disease and its Metal Chelation Therapeutics: A Narrative Review
Thakur, R., Karwasra, R., & Umar, T. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128263992231012113847 · Cited by 11
Ahmad, S., Alouffi, S., Shahab, U., Binsaleh, N. K., Ghoniem, M. E., Akasha, R., Ahmad, M. K., Ahmad, N., Waiz, M., & Khan, M. S. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105441 · Cited by 14
Sánchez-Puebla, L., de Hoz, R., Salobrar‐García, E., Vázquez, A. A., González-Jiménez, M., Ramirez, A. I., Fernández‐Albarral, J. A., Matamoros, J. A., Elvira‐Hurtado, L., Saido, T. C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158221 · Cited by 12
Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer’s Disease
Tian, J., Shi, J., Ni, J., Wei, M., Zhang, X., Chen, K., & Wang, Y.-Y. (2019) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-019-3066-y · Cited by 11
Falkenstein, M., Reiner‐Link, D., Živković, A., Gering, I., Willbold, D., & Stark, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116462 · Cited by 13
Khamle, A. R., Panda, S. K., Kore, V. D., Mukherjee, S., & Gupta, P. S. S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00329 · Cited by 10
Maria Jose Perez, J., Lam, A., Weissleder, C., Bertoli, F., Raji, H., Bosch, M., Nemazanyy, I., Kalb, S., Kehili, M., Hirschberg, I., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02320-1 · Cited by 18
Ikanga, J. N., Jean, K. R., Medina, P., Patel, S. S., Schwinne, M., Epenge, E., Gikelekele, G., Tshengele, N., Kavugho, I., Mampunza, S. M. M., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1477047 · Cited by 14
Blood-based biomarkers in mild behavioral impairment: an updated overview
Angelopoulou, E., Androni, X., Villa, C., Hatzimanolis, A., Scarmeas, N., & Papageorgiou, S. G. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1534193 · Cited by 14
Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment
Yang, Y., Koo, M., & Kwak, Y. T. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1639924 · Cited by 10
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease
Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 12
“At the molecular level, AD is characterised by the accumulation of extracellular β -amyloid (A β ) plaques and intracellular neurofibrillary tangles (NFTs) composed of p-tau protein [4,5].”
Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach
Haut, F., Argyrousi, E. K., & Arancio, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010259 · Cited by 11
“The results not only strengthen the utilization of oTau in CSF as an early biomarker for AD but also bring to light a possible physiological role for oTau in the healthy brain, similar to oA β [10].”
BackgroundResultSelf-citationCross-Linked Amyloid β-Protein Oligomers: A Missing Link in Alzheimer’s Disease Pathology?
Urbanc, B. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c07716 · Cited by 13
The dual-path hypothesis for the emergence of anosognosia in Alzheimer’s disease
Andrade, K. S., Guieysse, T., Medani, T., Koechlin, É., Pantazis, D., & Dubois, B. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1239057 · Cited by 11
Jarero-Basulto, J. J., Gasca-Martínez, Y., Rivera-Cervantes, M. C., Gasca‐Martínez, D., González, N., Beas‐Zárate, C., & Gudiño‐Cabrera, G. (2024) · NeuroSci · doi:10.3390/neurosci5020010 · Cited by 12
“This has led researchers to consider A β Os as a causal factor in early AD pathogenesis [4–6].”
RetractedKlotho overexpression protects human cortical neurons from β-amyloid induced neuronal toxicity
Shaker, M. R., Salloum‐Asfar, S., Taha, R. Z., Javed, I., & Wolvetang, E. J. (2025) · Molecular Brain · doi:10.1186/s13041-025-01199-6 · Cited by 10
“Despite extensive research, clinical trials targeting β-amyloid reduction, either by preventing its formation or clearing plaques, have yet to yield significant cognitive improvements in human patients [29].”
Zahariev, N., Boyuklieva, R., Penkov, D., Lukova, P., & Katsarov, P. (2025) · Materials · doi:10.3390/ma18184302 · Cited by 10
“…in amyloid-beta plaques and tau neurofibrillary tangles; in PD, alpha-synuclein aggregates form Lewy bodies; in HD, mutant huntingtin proteins with polyglutamine expansions accumulate; and in ALS and frontotemporal dementia, TAR DNA-binding protein 43 (TDP-43) aggregates are involved [56,57].”
The Molecular Architecture of Neurodegeneration: An Integrative Overview of Convergent Mechanisms
Aranda-Abreu, G. E., Rojas-Durán, F., Hernández‐Aguilar, M. E., Herrera‐Covarrubias, D., Tlapa-Monge, L. R., & Mestizo-Gutiérrez, S. L. (2026) · NeuroSci · doi:10.3390/neurosci7010007 · Cited by 13
“In AD, A β and Tau oligomers act as seeds that induce misfolding of normal proteins [60].”
Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease
Tyler, S. E. B., & Tyler, L. D. K. (2022) · Natural Products and Bioprospecting · doi:10.1007/s13659-022-00354-z · Cited by 10
Bhoopal, B., Gollapelli, K. K., Damuka, N., Miller, M. D., Krizan, I. M., Bansode, A. H., Register, T. C., Frye, B. M., Kim, J., Mintz, A., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00527 · Cited by 11
Plasma p-tau181 associated with structural changes in mild cognitive impairment
Nabizadeh, F., Balabandian, M., Rostami, M. R., Ward, R. T., Ahmadi, N., Pourhamzeh, M., & Initiative, A. D. N. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02148-2 · Cited by 10
“As several clinical trials focused on Aβ immunotherapy have failed, researchers have turned their attention to tauopathy to explore both the diagnostic and therapeutic approaches to AD [12, 13].”
BackgroundPrediction of the Clinical Severity of Progressive Supranuclear Palsy by Diffusion Tensor Imaging
Chen, Y.-L., Zhao, X., Ng, S., Lu, C., Lin, Y., Cheng, J., Tsai, C., & Wang, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010040 · Cited by 9
“It was postulated that the increase of amyloid-β (Aβ) might trigger tau pathology leading to the eventual neuronal death [38].”
Aβ oligomers: role at the synapse
Puzzo, D. (2019) · Aging · doi:10.18632/aging.101818 · Cited by 9
Self-citationMainali, N. (2024) · Bioinformation · doi:10.6026/973206300200004 · Cited by 8
A Structural Effect of the Antioxidant Curcuminoids on the Aβ(1–42) Amyloid Peptide
Santoro, A., Ricci, A., Rodriquez, M., Buonocore, M., & D’Ursi, A. M. (2025) · Antioxidants · doi:10.3390/antiox14010053 · Cited by 10
“Alzheimer’s disease (AD) is a neurodegenerative disease characterised by the progressive accumulation of amyloid– β (A β ) peptides and hyperphosphorylated tau, which form plaques and neurofibrillary tangles, respectively [1,2].”
A Novel Tandem-Tag Purification Strategy for Challenging Disordered Proteins
Mészáros, A., Muwonge, K., Janvier, S., Ahmed, J., & Tompa, P. (2022) · Biomolecules · doi:10.3390/biom12111566 · Cited by 10
Bogdan, S., Puścion‐Jakubik, A., Klimiuk, K., Socha, K., Kochanowicz, J., & Gorodkiewicz, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216855 · Cited by 9
“A new approach implicates the pathogenesis of AD, in which extracellular amyloid-β and tau oligomers act in parallel and upstream of the amyloid-β protein precursor (A β PP) [37].”
BackgroundTrisal, A., & Singh, A. K. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.01.004 · Cited by 9
Cantone, A. F., Burgaletto, C., Benedetto, G. D., Gaudio, G., Giallongo, C., Caltabiano, R., Broggi, G., Bellanca, C. M., Cantarella, G., & Bernardini, R. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10177-7 · Cited by 13
“…of potential pathogenetic factors (Vejandla et al. 2024), such as accumulation of amyloid-β (Aβ) and hyperphosphorylated tau (p-tau) in the brain (Gulisano et al. 2018), recently, neuroinflammation has been increasingly regarded as a crucial contributor to AD pathogenesis (Leng and Edison…”
Chami, M., & Checler, F. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200225102941 · Cited by 9
An, F.-M., Xuan, X., Liu, Z., Bian, M., Shen, Q., Quan, Z., Zhang, G., & Wei, C. (2022) · Molecules · doi:10.3390/molecules27155035 · Cited by 8
Hemmerová, E., Špringer, T., Krištofiková, Z., & Homola, J. (2020) · Biomolecules · doi:10.3390/biom10091214 · Cited by 8
Alsenani, F. (2024) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2024.103998 · Cited by 9
“A β deposits contribute to neurodegeneration, while NFTs, composed of aberrantly folded tau proteins, destabilize the microtubule network, a hallmark of AD (Gulisano et al., 2018).”
BackgroundAdvancements in ultrasound-mediated drug delivery for central nervous system disorders
Chuang, C.-F., Phan, T.-N., Fan, C., Le, T.-T. V., & Yeh, C. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2438188 · Cited by 10
“The main pathological features of AD are the accumulation of β-amyloid (Aβ) plaques [57] and tau protein tangles [58], which lead to neuronal dysfunction.”
Immunopathogenesis and target therapy of Alzheimer’s disease
Дмитриевна, Н. Е., Хасанова, Е. М., & Gankovskaya, L. V. (2023) · Immunologiya · doi:10.33029/0206-4952-2023-44-2-231-242 · Cited by 8
Santillán-Morales, V., Rodríguez-Espinosa, N., Muñoz‐Estrada, J., Alarcón-Elizalde, S., Acebes, Á., & Benítez‐King, G. (2024) · Brain Sciences · doi:10.3390/brainsci14010046 · Cited by 10
“Altered phosphorylation causes changes in the conformational state of tau, its microtubule detachment, and its propensity for aggregation [51].”
BackgroundSingh, K., Gupta, J. K., Narayan, S., Rani, K., Jain, D., Porwal, P., Sharma, M. C., & Kumar, S. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010298545241108062449 · Cited by 6
Ordaz, D. A., Gupta, K., & Bota, D. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1615843 · Cited by 8
“…ń ska and Rüdiger, 2021; McColgan and Tabrizi, 2018; Kumar and Ratan, 2016; Mehrabi et al., 2016; Kumar et al., 2023; Rajmohan and Reddy, 2017; Gulisano et al., 2018;Moreiraetal.,2022;Zhangetal.,2019;Piccaetal.,2021;Hagaetal.,2019;Kametal.,2020;Chenetal.,2022;Genoveseetal.,2022;Wangetal.,2023;…”
InfluentialIntrinsic Disorder and Other Malleable Arsenals of Evolved Protein Multifunctionality
Aftab, A., Sil, S., Nath, S., Basu, A., & Basu, S. (2024) · Journal of Molecular Evolution · doi:10.1007/s00239-024-10196-7 · Cited by 8
“Relatively newer findings show that both Aβ 42 and Tau oligomers bind to amyloid-β protein precursor (AβPP) (P05067) and enter neurons (Gulisano et al. 2018) to induce abnormal synaptic function and memory.”
Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6
Jain, M., Dhariwal, R., Bhardava, K., Das, S., Shaikh, M. S., Tendulkar, R., Wani, R., Sharma, M., Delta, A. K., & Kaushik, P. (2024) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2024.103022 · Cited by 9
Breaking Barriers in Alzheimer’s Disease: the Role of Advanced Drug Delivery Systems
Shekho, D., Mishra, R., Kamal, R., Bhatia, R., & Awasthi, A. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02923-6 · Cited by 6
“AD is marked by extracellular plaques containing amyloid-β (Aβ-40,42) and intracellular neurofibrillary tangles(NTs) containing tau protein [2].”
Muronets, V. I., Kudryavtseva, S. S., Kurochkina, L. P., Leisi, E. V., Stroylova, Y. Y., & Schmalhausen, E. V. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297924604003 · Cited by 5
“These data support the hypothesis that large fibrillar formations emerging during amyloid transformation of Aβ peptide may not be a major cause of the disease, but rather some defense mechanism protecting against neurotoxic effect of its pathological oligomeric species [6, 7].”
Sharma, A., Maity, S., Gupta, S., Ali, A., Ali, A., & Asati, V. (2025) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2025.101804 · Cited by 6
Xiong, C., Tang, Y., Chen, J., Fan, M., Wei, L., Dong, Z., Lai, X., Men, X., Chen, Q., Li, D., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00512-6 · Cited by 8
Neurodevelopmental origins of neurodegeneration: a lifespan perspective on brain vulnerability
Kopalli, S. R., Vadia, N., Varma, P., Mishra, S., Joshi, N., Bansal, P., Al-Hasnaawei, S., Chauhan, A. S., Jain, H., Nathiya, D., et al. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150134 · Cited by 9
Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy
Xu, X., Wang, X., Jiang, W., Kamaruddin, W. H. A., Fang, C., & Zhang, P. (2026) · BMEMat · doi:10.1002/bmm2.70080 · Cited by 5
Fu, Y., Zhang, J., Yang, C., Wang, Y., Yang, Y., Qiu, P., Xie, W., Zhang, S., & Lǚ, T. (2025) · International Journal of Toxicology · doi:10.1177/10915818251338235 · Cited by 6
Puzzo, D., & Conti, F. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.684977 · Cited by 6
“Yet, thousands of preclinical studies have documented a role for it in AD pathophysiology (Sauer, 2014; de la Torre, 2017; Kepp, 2017; Gulisano et al., 2018; Makin, 2018).”
BackgroundSelf-citationDaniele, F., Marasco, D., & Manna, S. L. (2024) · Inorganica Chimica Acta · doi:10.1016/j.ica.2024.122474 · Cited by 5
Elevated levels of salivary interleukin-34 in patients suffering from Alzheimer’s disease
Clark, R., Lira‐Junior, R., Jansson, L. E., Eriksdotter, M., Schultzberg, M., Pussinen, P. J., Buhlin, K., & Boström, E. A. (2025) · Clinical Oral Investigations · doi:10.1007/s00784-025-06376-4 · Cited by 7
Ali, M. A., Sayed, R. H., Wadie, W., & Mohammed, R. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177897 · Cited by 5
Vilella, A., Romoli, B., Bodria, M., Pons, S., Maskos, U., & Zoli, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1097857 · Cited by 5
“The interaction between Aβ and α7 nAChRs has been extensively investigated and is thought to mediate physiological effects of Aβ at low concentration and Aβ neurotoxicity at higher concentrations, possibly through internalization of the nAChR/Aβ complex (Farhat and Ahmed, 2017; Gulisano et al., 2019).”
Suri, K., Ramesh, M., Bhandari, M., Gupta, V., Kumar, V., Govindaraju, T., & Murugan, N. A. (2024) · ChemBioChem · doi:10.1002/cbic.202400224 · Cited by 5
Duncan, G. B., Dickson, S. P., Kaplan, J. M., Johnson, S. B., Duke, T. M., Dayley, C. W., Hendrix, S. B., Altstiel, L. D., & Mallinckrodt, C. H. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70183 · Cited by 5
Saad, H. M., Atef, E., Aboushouk, A. A., Waheeb, T. S., Elsayed, A., & Mohammed, S. A. A. (2026) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlag014 · Cited by 5
Miastenia gravis y enfermedad de Alzheimer: una asociación a estudio
Morales‐Casado, M. I., Diezma-Martín, A. M., Muñoz-Escudero, F., Calvo, S. R., Marín, B. M., Vadillo-Bermejo, A., Alonso, C. M., & Martín, P. B. (2024) · Revista de Neurología · doi:10.33588/rn.7802.2023120 · Cited by 4
“Fisiopatológicamente se caracteriza por la pre-sencia de placas neuríticas extracelulares formadas por proteína β-amiloide y acúmulos intracelulares neurofibrilares de proteína tau [8].”
BackgroundOchi, S., Yamada, K., Saito, T., Saido, T. C., Iinuma, M., Azuma, K., & Kubo, K. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1361847 · Cited by 5
“During senile plaque formation, tau phosphorylated by tau kinases, leading to the formation of tau aggregates, including highly phosphorylated paired helical filaments and neurofibrillary tangles, which are toxic to neurons and synapses (Gulisano et al., 2018; Zhang et al., 2021).”
BackgroundInfluentialMAMs and Mitochondrial Quality Control: Overview and Their Role in Alzheimer’s Disease
Luo, J.-S., Zhai, W.-H., Ding, L.-L., Zhang, X.-J., Han, J., Ning, J., Chen, X.-M., Jiang, W., Yan, R., & Chen, M. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04205-w · Cited by 4
“Additionally, studies have suggested that Aβ may not be correlated with the severity of dementia and elevated levels of Aβ do not cause evident clinical symptoms of AD [19 ].”
Pyka‐Fościak, G., Jasek-Gajda, E., Wójcik, B., LIS, G. J., & Litwin, J. A. (2024) · Biomedicines · doi:10.3390/biomedicines12122770 · Cited by 4
Biswal, B., Satapathy, B. S., Mishra, A., Maharana, L., & Pattnaik, S. (2025) · Current Drug Discovery Technologies · doi:10.2174/0115701638329824241220055621 · Cited by 4
Novel Nanoformulations to Overcome Obstacles in Herbal Drug Delivery for Alzheimer's Disease
Kumar, D., Wal, P., Wal, A., Lari, M. Q., Ashesh, A. M., Kumar, D., Singh, S. K., Singh, B., & Kumar, A. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266362594250527112018 · Cited by 4
Recent Advances and Future Directions in Alzheimer’s Disease Genetic Research
Stancheva, M., Toncheva, D. I., & Karachanak-Yankova, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167819 · Cited by 6
“On the other hand, the buildup of tau proteins, forming neurofibrillary tangles, is also commonly observed as a universal sign of neuron death [22].”
Huang, Y., Chan, H., Khoo, J.-Y., Chan, M.-L., Bender, D. A., Ponnusamy, V. K., Belaidi, A. A., & Ke, L. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106104 · Cited by 4
Górska, A. M., Santos‐García, I., Kvasnička, A., Dobešová, D., Friedecký, D., Gildenblat, J., & Pahnke, J. (2026) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2026.102891 · Cited by 6
Ginsenosides Decrease β-Amyloid Production via Potentiating Capacitative Calcium Entry
Cho, Y. Y., Park, J. H., Lee, J. H., & Chung, S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2023.172 · Cited by 5
Krämer, M., Hoang, T., Yang, H., Shchyglo, O., Böge, J., Neubacher, U., Colitti-Klausnitzer, J., & Manahan‐Vaughan, D. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1397901 · Cited by 6
“It has been demonstrated that endogenous A β promotes and supports hippocampal synaptic plasticity, a key mechanism in memory formation (Puzzo et al., 2008, 2011) and effects are concentration-dependent and largely enabled by A β monomers (Gulisano et al., 2018).”
BackgroundAran, K. R., Gupta, G. D., & Singh, S. (2024) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-024-00233-9 · Cited by 4
“Not only dementia but a few reports also emphasize the increased level of amyloid beta peptide (Aβ) and hyperphosphorylation of tau protein have been found in preclinical and clinical studies, which are responsible for producing AD-like symptoms [13].”
Nakano, H., Hikishima, S., Mori, M., Minamikawa, J., Muramatsu, D., Sakashita, Y., Ikeda, T., Noguchi‐Shinohara, M., Teplow, D. B., & Ono, K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106775 · Cited by 4
Xie, J., Tandon, R., & Mitchell, C. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031062 · Cited by 5
Tu, W., Li, J., & Meng, F. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003149 · Cited by 4
“To date, therapeutic strategies targeting the reduction of A β levels have been unsuccessful, and clinical trials focusing on tau have yet to yield positive results [ 4 ] .”
Cao, Q., Liu, J., Dong, P., & Han, H. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231199075 · Cited by 4
“27 However, there is also evidence that P-Tau can enhance A β toxicity through a feedback pathway 28 ; we, therefore, examined the effect of Schisandra-Evodia on the P-Tau protein and its molecular mechanism.”
BackgroundDementia and cognitive decline
Huq, A. J., Eratne, D., & Velakoulis, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99417-0.00006-9 · Cited by 4
Ikanga, J. N., Jean, K. R., Medina, P., Patel, S. S., Schwinne, M., Epenge, E., Gikelekele, G., Tshengele, N., Kavugho, I., Mampunza, S. M. M., et al. (2024) · medRxiv · doi:10.1101/2024.08.06.24311577 · Cited by 4
Stylianopoulou, E., Daviti, A., Giourou, V., Gerasimidi, E., Nikolaou, A., Kourkoutas, Y., Grigoriou, M. E., Paleologou, K. E., & Skavdis, G. (2023) · Brain Sciences · doi:10.3390/brainsci14010035 · Cited by 5
“Similarly to A β that is considered to play a key role in AD pathogenesis (reviewed in [27]), α -synuclein ( α -syn) aggregation is believed to be central to the pathogenesis of a series of neurodegenerative diseases collectively referred to as “synucleinopathies” (reviewed in [28]), with…”
BackgroundZhao, H., Huang, T., Dhavale, D. D., O’Shea, J. Y., Lengyel‐Zhand, Z., Guarino, D. S., Gu, J., Yue, X., Nai, Y., Jiang, H., et al. (2025) · Cells · doi:10.3390/cells14141108 · Cited by 5
“Two different insoluble protein aggregates are recognized as pathological hallmarks in AD: (1) the aggregation of amyloid-beta (A β ) peptides to form extracellular senile plaques (SPs); (2) the aggregation of the tau protein to form the intracellular neurofibrillary tangles (NFTs) [4].”
Ikanga, J. N., Jean, K. R., Medina, P., Patel, S. S., Schwinne, M., Epenge, E., Gikelekele, G., Tshengele, N., Kavugho, I., Mampunza, S. M. M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251360697 · Cited by 4
Matuszewski, W., Tomaszek, L., Szklarz, M., Górny, J. M., Kordas, B., Rutkowska, J., & Juranek, J. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186348 · Cited by 4
“Key mechanisms in AD include the accumulation of amyloid-beta plaques, the formation of neurofibrillary tangles of hyperphosphorylated tau protein, and processes such as oxidative stress, inflammation, and mitochondrial dysfunction [25,26].”
Elecsys CSF AD immunoassays: Sample stability for a new pre‐analytical protocol for fresh CSF
Manuilova, E., Schrurs, I., Rutz, S., McIlwrick, S., Goldhardt, O., Sommer, P., & Grimmer, T. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70797 · Cited by 5
Therapeutic Potentials of the Seaweed-Derived Compounds for Alzheimer’s Disease
Ward, K., Cole, M. H., Griffiths, L. R., Sutherland, H. G. E., Winberg, P. C., Meyer, B. J., & Fernandez, F. (2025) · Molecules · doi:10.3390/molecules30224456 · Cited by 4
Babu, K. S., Gupta, V., Dar, A. A., Sheikh, J. A., Kumar, D., Choudhary, N., Tanwar, R., Gupta, S., Rani, P., & Arunprasad, V. K. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2603409 · Cited by 7
“In addition to neuroinflammation and oxidative damage, crocetin has been proven to alter the insulin signaling pathway in rodents consuming Western diets (Gulisano et al., 2018; Timofeeva et al., 2025; Wisniewski & Sigurdsson, 2010).”
NLRP3 Inflammasome Activation in Oxidative Stress: A Key Mechanism Driving Neuroinflammation
Ramirez-Celis, C., Martínez-Torres, A. M., & Morán, J. (2026) · NeuroImmunoModulation · doi:10.1159/000551943 · Cited by 3
Amyloid and tau pathologies are drivers of white matter damage in aging and Alzheimer’s disease
Kamal, F., & Dadar, M. (2026) · GeroScience · doi:10.1007/s11357-026-02357-x · Cited by 4
Exploring Withanolides from Withania somnifera: A Promising Avenue for Alzheimer’s Disease Treatment
Pullaiah, C. P., Preethi Priyadharshini, S. P., Phareedha, S. K., Yamini, N., Birudala, G., Lahari, S., Vippamakula, S., Shakila, R., Ganjayi, M. S., & Raghavendra, M. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00394-2 · Cited by 5
“Similarly, another significant mechanism involved in the pathogenesis of AD is the accumulation of Aβ oligomers in neuroblastoma cells, and functional neurons in the hippocampus lead to neurodegeneration, followed by neuroapoptosis [102].”
Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies
Rathee, S., Pandey, V., Soni, S., Sen, D., & Jain, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050368798250626075628 · Cited by 8
Role of the U1 snRNP Complex in Human Health and Disease
Soares, E. S., Leal, C. B. Q. D. S., Sinatti, V. V. C., Bottos, R. M., & Zimmer, C. G. M. (2025) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.70026 · Cited by 5
The US9-derived protein gPTB9TM modulates APP processing without targeting secretase activities
Brandimarti, R., Irollo, E., & Meucci, O. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03153-2 · Cited by 3
Metadata
- Authors
- Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., Puzzo, D., & Arancio, O.
- Affiliations
- University of Catania (IT)
- Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY, USA
- Columbia University (US)
- Università Cattolica del Sacro Cuore (IT)
- Department of Pharmacology, Physiology and Neuroscience, Rutgers University, Newark, NJ, USA
- Corresponding author
- Puzzo, Daniela
- Arancio, Ottavio
- ORCID
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2018-06-12
- Volume
- 64
- Issue
- s1
- Pages
- S611-S631
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC8371153
- OpenAlex
- W2807540667
- Cited by
- 313
- References
- 223
- Citations by year
- 2026: 59 · 2025: 92 · 2024: 60 · 2023: 32 · 2022: 23 · 2021: 17 · 2020: 18 · 2019: 10 · 2018: 2
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- Funders
- National Institute on Aging (R01AG049402, R01AG017761)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta
- MeSH terms
- Alzheimer Disease, Animals, Humans, Signal Transduction, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.